p38 MAPK and MAPKAP-K2 inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug Namep38 MAPK and MAPKAP-K2 inhibitors (Boehringer Ingelheim)

Drug Alias NameMK-2 inhibiting carboline/pyrazinoindolone analogs (Boehringer Ingelheim)MAPKAP-K2 inhibiting carboline/pyrazinoindolone analogs (Boehringer Ingelheim)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitorsMAP kinase-activated protein kinase 2 inhibitors

TargetsMAP kinase-activated protein kinase 2P38 α mitogen-activated protein kinase

Therapy Area/IndicationsInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBoehringer Ingelheim Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBoehringer Ingelheim Corp

Active IndicationsN/A

Inactive IndicationsInflammation

Other Information

ATC CodeN/A